Your Immune System Has a Real Estate Problem

Location, location, location. It's the oldest cliche in real estate - and apparently, your immune system took it literally.

For years, cancer researchers have been obsessed with counting immune cells inside tumors. More T cells = better, right? Well, not so fast. A new review in the Annual Review of Immunology by Slingerland, Runderkamp, and Thommen basically says: it's not just about who shows up to the party, it's about where they're standing and who they're standing next to (Slingerland et al., 2026).

The Neighborhood Watch Program You Didn't Know You Had

Your immune system doesn't just scatter cells randomly through a tumor like confetti at a parade. Instead, immune cells organize themselves into what researchers call "immune niches" - specialized little neighborhoods within the tumor where cells cluster together, share signals, and coordinate their attack (or, sometimes, their very unfortunate surrender).

Think of it like this: if your tumor were a city, the immune cells aren't just wandering tourists. They're setting up shop. Some are building full-on community centers - complete with B cells, T cells, and dendritic cells all working together in organized structures. Others are huddled in dark alleys, getting bullied by the tumor into doing absolutely nothing useful.

The wild part? The arrangement of these cells predicts how well a patient responds to immunotherapy better than just counting how many immune cells showed up. Your oncologist might care less about the headcount and more about the seating chart.

Tertiary Lymphoid Structures: The Pop-Up Immune Bases

The rockstars of immune niches are tertiary lymphoid structures, or TLS. These are basically mini lymph nodes that your body builds inside the tumor - improvised immune command centers that weren't part of the original blueprint.

Back in 2020, three landmark studies published simultaneously in Nature showed that tumors with mature TLS responded dramatically better to immunotherapy (Helmink et al., 2020); (Cabrita et al., 2020). B cells, which had been flying under the radar in cancer research for years, turned out to be critical players inside these structures. It was the immunology equivalent of realizing the quiet kid in class was actually running the whole operation.

But here's the catch: not all TLS are created equal. Some are mature, well-organized, and pumping out anti-tumor responses like a well-oiled machine. Others are immature or, worse, infiltrated by regulatory cells that essentially flip them from "attack mode" to "stand down." Same structure, completely different outcome.

When the Security Team Gets Locked Out

The review also digs into how tumors manipulate these niches to their advantage. Cancer cells are spectacularly good at reshaping their local environment - suppressing helpful immune signals, recruiting regulatory T cells, and creating metabolic dead zones where T cells basically run out of gas (Thommen & Schumacher, 2018).

Thommen's group at the Netherlands Cancer Institute has been studying this for years. They've shown that T cells inside tumors exist on a whole spectrum of dysfunction - from "slightly tired" to "completely checked out." And where a T cell sits physically within the tumor determines a lot about which end of that spectrum it lands on. T cells hanging out near dendritic cells and in organized niches tend to stay more functional. T cells deep inside the tumor nest, surrounded by cancer cells and unfriendly macrophages? They're toast.

So What Do We Do About It?

This is where things get genuinely exciting. If spatial organization matters this much, then maybe we don't just need drugs that wake up immune cells - we need strategies that help them organize. Researchers are now exploring ways to induce TLS formation in tumors that don't naturally build them, essentially tricking cold tumors into creating their own immune infrastructure.

Some approaches use combinations of chemokines and cytokines to recruit the right cells to the right spots. Others aim to remodel the tumor vasculature so immune cells can actually get inside. It's less "send in the troops" and more "build the barracks first."

The review makes a compelling case that the next generation of immunotherapy won't just ask "are immune cells present?" but rather "are they in the right place, talking to the right neighbors, with the right resources?" Cancer treatment, it turns out, might need a better urban planner.

References:

1. Slingerland N, Runderkamp E, Thommen DS. Immune Niches in Cancer. Annual Review of Immunology. 2026. DOI: 10.1146/annurev-immunol-082724-123843. PMID: 41824327.

2. Helmink BA, Reddy SM, Gao J, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549-555. DOI: 10.1038/s41586-019-1922-8. PMID: 31942075.

3. Cabrita R, Lauss M, Sber A, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561-565. DOI: 10.1038/s41586-019-1914-8. PMID: 31942071.

4. Thommen DS, Schumacher TN. T Cell Dysfunction in Cancer. Cancer Cell. 2018;33(4):547-562. DOI: 10.1016/j.ccell.2018.03.012. PMID: 29634943.

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.